Search research articles
Contact Us
Filters
Showing results (311-320 of 325) with videos related to
Page
of 33
Sort By:
Blood Cancer Journal
|
December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
J R Jones, D A Cairns, W M Gregory, et al.
Leukemia
|
January 22, 2010
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia
J M Allan, N J Sunter, J R Bailey, et al.
BMC Rheumatology
|
July 19, 2021
BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
Fiona Rayner, Amy E Anderson, Kenneth F Baker, et al.
Lancet (London, England)
|
February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
Andrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
American Journal of Epidemiology
|
July 14, 2011
The PhenX Toolkit: get the most from your measures
Carol M Hamilton, Lisa C Strader, Joseph G Pratt, et al.
The Lancet. Rheumatology
|
January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial
Andrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Science Translational Medicine
|
July 26, 2023
Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes
Kelsey N Thompson, Kevin S Bonham, Nicholas E Ilott, et al.
Trials
|
July 17, 2019
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol
Mariam Al-Laith, Marianna Jasenecova, Sonya Abraham, et al.
Leukemia
|
November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk
G P Sava, H E Speedy, M C Di Bernardo, et al.
RMD Open
|
February 11, 2026
Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis
Sumera Qureshi, Maryam Adas, Phoebe J Cope, et al.
Page
of 33
Search research articles
Search
Showing results (311-320 of 325) with videos related to
Sort By:
Page
of 33
Blood Cancer Journal
|
December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
J R Jones, D A Cairns, W M Gregory, et al.
Leukemia
|
January 22, 2010
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia
J M Allan, N J Sunter, J R Bailey, et al.
BMC Rheumatology
|
July 19, 2021
BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
Fiona Rayner, Amy E Anderson, Kenneth F Baker, et al.
Lancet (London, England)
|
February 16, 2024
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
Andrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
American Journal of Epidemiology
|
July 14, 2011
The PhenX Toolkit: get the most from your measures
Carol M Hamilton, Lisa C Strader, Joseph G Pratt, et al.
The Lancet. Rheumatology
|
January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial
Andrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.
Science Translational Medicine
|
July 26, 2023
Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes
Kelsey N Thompson, Kevin S Bonham, Nicholas E Ilott, et al.
Trials
|
July 17, 2019
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol
Mariam Al-Laith, Marianna Jasenecova, Sonya Abraham, et al.
Leukemia
|
November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk
G P Sava, H E Speedy, M C Di Bernardo, et al.
RMD Open
|
February 11, 2026
Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis
Sumera Qureshi, Maryam Adas, Phoebe J Cope, et al.
Page
of 33